CRNX · Crinetics Pharmaceuticals, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-02 | Vivaldi Coelho Rogerio |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $40.00 per share. |
Common Stock
|
3,000 |
| 2026-06-18 | WIERENGA WENDELL |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
9,730 |
| 2026-06-18 | Fust Matthew K |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Common Stock
|
5,925 |
| 2026-06-18 | Deardorf Caren |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Common Stock
|
5,925 |
| 2026-06-18 | Bedrosian Camille L |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Common Stock
|
5,925 |
| 2026-06-18 | Vivaldi Coelho Rogerio |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
9,730 |
| 2026-06-18 | Bedrosian Camille L |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
9,730 |
| 2026-06-18 | Vivaldi Coelho Rogerio |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Common Stock
|
5,925 |
| 2026-06-18 | Okey Stephanie |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Common Stock
|
5,925 |
| 2026-06-18 | WIERENGA WENDELL |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Common Stock
|
5,925 |
| 2026-06-18 | Nichols Weston |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Common Stock
|
5,925 |
| 2026-06-18 | Nichols Weston |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
9,730 |
| 2026-06-18 | Fust Matthew K |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
9,730 |
| 2026-06-18 | Deardorf Caren |
Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
9,730 |
| 2026-06-18 | Okey Stephanie |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
9,730 |
| 2026-06-17 | Okey Stephanie |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $35.62 per share. The range of sale prices on the transaction date was $35.19 to $36.06. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
Common Stock
|
6,292 |
| 2026-06-17 | Okey Stephanie |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $36.22 per share. The range of sale prices on the transaction date was $36.19 to $36.29. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
Common Stock
|
608 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↓
Filing footnotes — Common Stock (Indirect)
(3) Represents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust ("Family Trust 7") and (b) the RSS Dynasty Trust ("Family Trust 8"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
111,100 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↓
Filing footnotes — Common Stock (Direct)
(2) Represents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust ("Family Trust 5") and (b) the JSS Dynasty Trust ("Family Trust 6"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. |
Common Stock
|
111,100 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↑
Filing footnotes — Common Stock (Indirect)
(1) Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
80,000 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↑
Filing footnotes — Common Stock (Indirect)
(3) Represents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust ("Family Trust 7") and (b) the RSS Dynasty Trust ("Family Trust 8"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
111,100 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↓
Filing footnotes — Common Stock (Direct)
(2) Represents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust ("Family Trust 5") and (b) the JSS Dynasty Trust ("Family Trust 6"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. |
Common Stock
|
111,100 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↓
Filing footnotes — Common Stock (Indirect)
(3) Represents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust ("Family Trust 7") and (b) the RSS Dynasty Trust ("Family Trust 8"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
111,100 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↑
Filing footnotes — Common Stock (Indirect)
(2) Represents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust ("Family Trust 5") and (b) the JSS Dynasty Trust ("Family Trust 6"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
111,100 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↓
Filing footnotes — Common Stock (Indirect)
(1) Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
80,000 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↑
Filing footnotes — Common Stock (Indirect)
(3) Represents contributions of shares by the Reporting Person's spouse to (a) the Iowa Descendants Trust ("Family Trust 7") and (b) the RSS Dynasty Trust ("Family Trust 8"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person and his family members are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
111,100 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↓
Filing footnotes — Common Stock (Indirect)
(1) Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
222,200 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↑
Filing footnotes — Common Stock (Direct)
(1) Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein. |
Common Stock
|
222,200 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↑
Filing footnotes — Common Stock (Indirect)
(1) Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
222,200 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↓
Filing footnotes — Common Stock (Indirect)
(1) Represents gifts of shares by the Struthers Family Trust ("Family Trust 1"), of which the Reporting Person is the trustee and the Reporting Person and his spouse are beneficiaries, to (a) the Reporting Person, (b) the Reporting Person's spouse and (c) the Struthers Family Charitable Remainder Trust (the "Charitable Trust"), a charitable remainder trust of which the Reporting Person is the trustee and of which the Reporting Person and his spouse are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by the Charitable Trust except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
222,200 |
| 2026-05-29 | Struthers Richard Scott |
Director, President & CEO |
Gift↑
Filing footnotes — Common Stock (Indirect)
(2) Represents contributions of shares by the Reporting Person to (a) the GMS Dynasty Trust ("Family Trust 5") and (b) the JSS Dynasty Trust ("Family Trust 6"), each of which is an irrevocable trust with an independent trustee of which the Reporting Person's spouse and her family members, and the Reporting Person's spouse, respectively, are beneficiaries. The Reporting Person disclaims beneficial ownership of the shares held by Family Trust 5 and Family Trust 6 except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
111,100 |
| 2026-04-08 | Knight Jeff E. |
Chief Dev. & Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $40.10 per share. The range of sale prices on the transaction date was $40.00 to $40.34. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
Common Stock
|
85,163 |
| 2026-04-08 | Knight Jeff E. |
Chief Dev. & Operating Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares subject to the option vested on August 30, 2022, and the remaining number of shares subject to the option vested monthly thereafter in thirty-six equal installments. |
Stock Option (Right to Buy)
|
49,474 |
| 2026-04-08 | Knight Jeff E. |
Chief Dev. & Operating Officer |
Convert↑
|
Common Stock
|
9,624 |
| 2026-04-08 | Knight Jeff E. |
Chief Dev. & Operating Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the shares subject to the option vested monthly measured from the vesting commencement date of February 28, 2022. |
Stock Option (Right to Buy)
|
9,624 |
| 2026-04-08 | Knight Jeff E. |
Chief Dev. & Operating Officer |
Convert↑
|
Common Stock
|
19,336 |
| 2026-04-08 | Knight Jeff E. |
Chief Dev. & Operating Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option is exercisable as follows: 1/48th of the shares subject to the option vest monthly measured from the vesting commencement date of March 1, 2023, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
19,336 |
| 2026-04-08 | Knight Jeff E. |
Chief Dev. & Operating Officer |
Convert↑
|
Common Stock
|
49,474 |
| 2026-03-16 | Struthers Richard Scott |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
Common Stock
|
13,196 |
| 2026-03-16 | Struthers Richard Scott |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
Common Stock
|
8,785 |
| 2026-03-16 | Knight Jeff E. |
Chief Dev. & Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
Common Stock
|
3,961 |
| 2026-03-16 | Betz Stephen F. |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
Common Stock
|
6,371 |
| 2026-03-16 | Knight Jeff E. |
Chief Dev. & Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
Common Stock
|
5,950 |
| 2026-03-16 | Betz Stephen F. |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
Common Stock
|
4,241 |
| 2026-03-12 | Vivaldi Coelho Rogerio |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $36.77 per share. The range of sales prices on the transaction date was $36.69 to $36.89 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
Common Stock
|
523 |
| 2026-03-12 | Vivaldi Coelho Rogerio |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $36.08 per share. The range of sales prices on the transaction date was $35.65 to $36.53 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. |
Common Stock
|
4,477 |
| 2026-03-03 | Okey Stephanie |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $39.67 per share. |
Common Stock
|
3,000 |
| 2026-03-03 | Schilke Tobin |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 10, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $39.67 per share. The range of sales prices on the transaction date was $39.67 to $39.74 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. |
Common Stock
|
6,713 |
| 2026-02-23 | Knight Jeff E. |
Chief Dev. & Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026. |
Stock Option (Right to Buy)
|
55,000 |
| 2026-02-23 | Betz Stephen F. |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026. |
Stock Option (Right to Buy)
|
47,000 |